James Healy, MD, PhD

General Partner

Jim Healy, MD, PhD, has over 20 years of experience in bio-medical research, development, and finance. Dr. Healy joined Sofinnova in 2000 as a General Partner, and specializes in funding private and publicly traded bio-pharmaceutical companies. Jim has financed and served on the board of ten companies which received drug approvals from either the FDA or EMA. He was an early investor and board member of thirteen companies which subsequently completed initial public offerings and ten companies that have been acquired as private or public companies. He invests throughout the US and Europe.

Previous investments and board memberships include Anthera Pharmacueticals (ANTH), Cellective Therapuetics (acquired by AstraZeneca), CoTherix (CTRX, acquired by Actelion), Durata Therapuetics (DRTX, acquired by Actavis), InterMune (ITMN, acquired by Roche), KaloBios (KBIO), Movetis (MOVE, acquired by Shire), NextWave Pharmacueticals (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter), Prestwick (acquired by Biovail) and Salveo Specialty Pharmacy (acquired by Catamaran).

Jim presently serves on the board of directors of Amarin (AMRN), Auris (EARS), Coherus (CHRS), Edge (EDGE), and is the Chairman of the Board at Hyperion (HPTX). He also serves on the board of directors of Ascendis, NuCana and other private companies.

In 2011 Jim won the IBF Risk Master Innovator Award and was named as one of the industry's top Life Science investors in 2013 by Forbes Magazine. Jim is a Director on the Board of the National Venture Capital Association (NVCA) and has been appointed to the Emerging Companies Section Governing Board of the Biotechnology Industry Organization (BIO).

Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California at Berkeley and has lectured on entrepreneurship at Stanford University. Prior to Sofinnova, Jim worked at Bayer (Miles), Sanderling, and consulted at ISTA Pharmaceuticals.

Jim graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors and received a Departmental Citation. Jim received his MD and PhD in Immunology from Stanford University School of Medicine through the NIH Medical Scientist Training Program. He was a Beckman Scholar, received a Novartis Bursary Award and performed neuroscience research at the University of Virginia School of Medicine. Jim has authored or co-authored thirteen peer reviewed articles and invited reviews, including three papers published in Nature. He lived in Denmark, speaks Danish, and enjoys skiing.

Assistant: Tiffany Davis Email: tiffany@sofinnova.com


(650) 681-8422


Representative Investments